China's Brii Biosciences has said lab studies showed that its Covid-19 antibody cocktail retained activity against the Omicron variant, although one of the antibodies showed a substantial drop in activity when tested alone, Reuters reports.

Test details for the dual-antibody treatment, which last week became the first approved Covid-19 antibody cocktail in China, would not be available until publication in a scientific journal, but results from three independent labs showed a similar pattern, Brii chief executive Hong Zhi has said.

Although no purchase order for the treatment has been announced, the firm was able to secure manufacturing capacity of 1 million doses for 2022 and 2023 each, Hong said in an investor call, adding it already has about 80,000 doses available in its inventory.